Heparin-triggered release of camouflaged tissue plasminogen activator for targeted thrombolysis

Journal of Controlled Release

Volumn 157, Issue 1, 2012, Pages 46-54

  Absar, Shahriar ^a   Choi, Suna ^a   Yang, Victor C ^b   Kwon, Young M ^a  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Keywords; Targeted thrombolysis; Tissue plasminogen activator (tPA); Triggered release

Indexed keywords

ACTIVATED PARTIAL THROMBOPLASTIN TIME; ENZYMATIC ACTIVITIES; ENZYME ACTIVATION; HUMAN BLOODS; IN-VITRO; IN-VIVO; JUGULAR VEINS; KEYWORDS; LOW-MOLECULAR WEIGHT HEPARINS; MYOCARDIAL INFARCTION; PRODRUGS; PROOF OF PRINCIPLES; THROMBOLYSIS; TISSUE PLASMINOGEN ACTIVATOR; TISSUE PLASMINOGEN ACTIVATOR (TPA); TRIGGERED RELEASE;

CHEMICAL ACTIVATION; TISSUE;

POLYSACCHARIDES;

ALBUMIN CONJUGATE; ALBUMIN PROTAMINE CONJUGATE; LOW MOLECULAR WEIGHT HEPARIN; PROTAMINE; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD CLOT LYSIS; COMPLEX FORMATION; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG STABILITY; ENZYME ACTIVITY; HEART INFARCTION; JUGULAR VEIN; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; RAT; THROMBOSIS;

ANIMALS; DELAYED-ACTION PREPARATIONS; DRUG DELIVERY SYSTEMS; HEPARIN; HUMANS; RATS; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR; VENOUS THROMBOSIS;

EID: 84855825368     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2011.09.060     Document Type: Article

References (41)

1. M. Løvlien, I. Johansson, T. Hole, and B. Schei Early warning signs of an acute myocardial infarction and their influence on symptoms during the acute phase, with comparisons by gender Gend. Med. 6 3 2009 444 453
2. N. Mackman Triggers, targets and treatments for thrombosis Nature 451 2008 914 918
3. J.B. Segal, J. Eng, L.J. Tamariz, and E.B. Bass Review of the evidence on diagnosis of deep venous thrombosis and pulmonary embolism Ann. Fam. Med. 5 2007 63 73 (Pubitemid 46193209)
4. H.V. Anderson, and J.T. Willerson Thrombolysis in acute myocardial infarction N. Engl. J. Med. 329 1993 703 709 (Pubitemid 23252265)
5. D. Kleindorfer, C. Lindsell, L. Brass, W. Koroshetz, and J. Broderick National US estimates of recombinant tissue plasminogen activator use Stroke 39 2008 924 928
6. L. Machado, I. Sazonova, A. Kozak, D. Wiley, A. El-Remessy, A. Ergul, D. Hess, J. Waller, and S. Fagan Minocycline and tissue-type plasminogen activator for stroke: assessment of interaction potential Stroke 40 2009 3028 3033
7. W. Bennett, N. Paoni, B. Keyt, D. Botstein, A. Jones, L. Prestal, F. Wurm, and M. Zoller High resolution analysis of functional determination of human tissue-type plasminogen activator J. Biol. Chem. 266 1991 5191 5520
8. E. Grossbard Recombinant tissue plasminogen activator: a brief review Pharm. Res. 4 1987 375 378 (Pubitemid 18010565)
9. H. Berger, and S. Pizzo Preparation of polyethylene glycol-tissue plasminogen activator adducts that retain functional activity: characteristics and behavior in three animal species Blood 71 1988 1641 1647
10. W. Chandler, M. Alessi, M. Aillaud, P. Henderson, P. Vague, and I. Juhan-Vague Clearance of tissue plasminogen activator (TPA) and TPA/plasminogen activator inhibitor type 1 (PAI-1) complex Circulation 96 1997 761 768
11. J. Humphries, C. Lattimer, A. Smith, C. McGuinness, C. Whitton, P. Gaffney, and K. Bumand High and constant plasma levels of tissue plasminogen activator and PEG-Hirudin can be achieved by subcutaneous delivery Thromb. Res. 87 1997 123 129 (Pubitemid 27333269)
12. 2-antiplasmin: complementary roles in regulating lysis of thrombi and plasma clots J. Thromb. Haemost. 5 2007 812 817 (Pubitemid 46563582)
13. R.B. Stricker, D. Wong, D.T. Shiu, P.T. Reyes, and M.A. Shuman Activation of plasminogen by tissue plasminogen activator on normal and thrombasthenic platelets: effects on surface proteins and platelet aggregation Blood 68 1986 275 280 (Pubitemid 16033642)
14. V.J. Marder, and N.R. Shulman High molecular weight derivatives of human fibrinogen produced by plasmin. II. Mechanism of their anticoagulant activity J. Biol. Chem. 244 1969 2120 2124
15. M. Redondo, C. Caliezi, F.D. Biasiutti, B. Lammle, and W.A. Wuillemin Increased fibrin monomer plasma concentration in stable coronary artery disease in patients without oral anticoagulation Atherosclerosis 157 2001 417 422 (Pubitemid 32710021)
16. H. Wada, Y. Wakita, T. Nakase, M. Shimura, K. Hiyoyama, S. Nagaya, H. Deguchi, Y. Mori, T. Kaneko, K. Deguchi, J. Fujii, and H. Shiku Increased plasma-soluble fibrin monomer levels in patients with disseminated intravascular coagulation Am. J. Hematol. 51 1996 255 260 (Pubitemid 26117539)
17. K. Stangl, M. Laule, B. Tenckhoff, V. Stangl, V. Gliech, P. Dubel, A. Grohmann, C. Melzer, J. Langel, K.D. Wernecke, G. Baumann, and S. Ziemer Fibrinogen breakdown, long-lasting systemic fibrinolysis, and procoagulant activation during alteplase double-bolus regimen in acute myocardial infarction Am. J. Cardiol. 81 1998 841 847 (Pubitemid 28204637)
18. A.M. Piras, F. Chiellini, C. Fiumi, C. Bartoli, E. Chiellini, B. Fiorentino, and C. Farina A new biocompatible nanopartcle delivery system for the release of fibrinolytic drugs Int. J. Pharm. 357 2008 260 271
19. J.Y. Kim, J.K. Kim, J.S. Park, Y. Byun, and C.K. Kim The use of PEGylated liposomes to prolong circulation lifetimes of tissue plasminogen activator Biomaterials 30 2009 5751 5756
20. Y. Park, J. Liang, Z. Yang, and V.C. Yang Controlled release of clot-dissolving tissue-type plasminogen activator from a poly(L-glutamic acid) semi-interpenetrating polymer network hydrogel J. Control. Release 75 1-2 2001 37 44 (Pubitemid 32635195)
21. T. Yamada, S. Yoshimi, and M. Kikuchi Integrin-specific tissue plasminogen activator engineered by introduction of the Arg-Gly-Asp sequence Biochem. Biophys. Res. Commun. 228 1996 306 311 (Pubitemid 26396070)
22. S. Naik, J. Liang, Y. Park, W. Lee, and V.C. Yang Application of "ATTEMPTS" for drug delivery J. Control. Release 101 2005 35 45
23. J.F. Liang, Y.J. Park, H. Song, Y.T. Li, and V.C. Yang ATTEMPTS: a heparin/protamine-based prodrug approach for delivery of thrombolytic drugs J. Control. Release 72 1-3 2001 145 156 (Pubitemid 32522352)
24. J.F. Liang, Y.T. Li, H. Song, Y.J. Park, S.S. Naik, and V.C. Yang ATTEMPTS: a heparin/protamine-based delivery system for enzyme drugs J. Control. Release 78 1-3 2002 67 79 (Pubitemid 34081854)
25. V.C. Yang, S.S. Naik, H. Song, A.A. Dombkowski, G. Crippen, and J.F. Liang Construction and characterization of a t-PA mutant for use in ATTEMPTS: a drug delivery system for achieving targeted thrombolysis J. Control. Release 110 1 2005 164 176 (Pubitemid 41713940)
26. Y.M. Kwon, Y. Li, S. Naik, J.F. Liang, Y. Huang, Y.J. Park, and V.C. Yang The ATTEMPTS delivery systems for macromolecular drugs Expert Opin. Drug Deliv. 5 11 2008 1255 1266
27. Y. Uesugi, H. Kawata, J. Jo, Y. Saito, and Y. Tabata An ultrasound-responsive nano delivery system of tissue-type plasminogen activator for thrombolytic therapy J. Control. Release 147 2 2010 269 277
28. M.D. Kaminski, Y. Xie, C.J. Mertz, M.R. Finck, H. Chen, and A.J. Rosengart Encapsulation and release of plasminogen activator from biodegradable magnetic microcarriers Eur. J. Pharm. Sci. 35 2008 96 103
29. D. Choi, K. Hwang, K. Lee, and Y. Kim Ischemic heart disease: current treatments and future J. Control. Release 140 2009 194 202
30. R.C. Becker, and F.A. Spencer Fibrinolytic and Antithrombotic Therapy: Theory, Practice, and Management 2nd ed 2006 Oxford Univ. Press New York 96
31. B. Coller, J. Kutok, L. Scudder, D. Galanakis, S. West, G. Rudomen, and K. Springer Studies of activated GPllb/llla receptors on the luminal surface of adherent platelets J. Clin. Invest. 92 1993 2796 2806
32. S. Ware, J.P. Donahue, J. Hawiger, and W.F. Anderson Structure of the fibrinogen γ-chain integrin binding and factor XIIIa cross-linking sites obtained through carrier protein driven crystallization Prot. Sci. 8 1999 2773-2671
33. F. Kratz Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles J. Control. Release 132 3 2008 171 183
34. K. Mori, R.A. Dwek, K. Downing, G. Opdenakker, and P.M. Rudd The activation of type 1 and type 2 plasminogen by type 1 and type 2 tissue plasminogen activator J. Biol. Chem. 270 1995 3261 3267
35. S. Bai, and F. Ahsan Inhalable liposomes of low molecular weight heparin for the treatment of venous thromboembolism J. Pharm. Sci. 99 11 2010 4554 4564
36. W.P. Jeske, O. Iqbal, J. Fareed, and B. Kaiser A survey of venous thrombosis models Meth. Mol. Med. 93 2004 221 237
37. B. Johnstone The activated partial thromboplastin time of diluted plasma: variability due to method of fibrin detection Can. J. Comp. Med. 48 1984 198 201
38. K. Troung, and M. Ikura The use of FRET imaging microscopy to detect protein-protein interactions and protein conformational changes in vivo Curr. Opin. Struct. Biol. 11 2001 573 578 (Pubitemid 32972019)
39. P. Carmeliet, and D. Collen Gene targeting and gene transfer studies of the plasminogen/plasmin system: implications in thrombosis, hemostasis, neointima formation, and atherosclerosis FASEB J. 9 1995 934 938
40. L.C. Chang, H.F. Lee, M.J. Chung, and V.C. Yang PEG-modified protamine with improved pharmacological/pharmaceutical properties as a potential protamine substitute: synthesis and in vitro evaluation Bioconjug. Chem. 16 1 2005 147 155 (Pubitemid 40129688)
41. T.D. Bjornsson, and G. Levy Pharmacokinetics of heparin. I. Studies of dose-dependence in rats J. Pharmacol. Exp. Ther. 210 2 1979 237 242 (Pubitemid 9250831)